## Why "Activation of pre-synaptic α2 receptors in the brainstem inhibits sympathetic outflow" is right Clonidine is a centrally-acting α2 agonist that binds to pre-synaptic α2 receptors in the brainstem, particularly in the rostral ventrolateral medulla. This activation suppresses sympathetic neurotransmitter release, leading to decreased peripheral sympathetic activity, which results in reduced blood pressure and heart rate. This is the primary mechanism of clonidine's antihypertensive effect and is the textbook mechanism described in KD Tripathi 9e Ch 36. ## Why each distractor is wrong - **Blockade of post-synaptic α1 receptors in vascular smooth muscle causes vasodilation**: This describes the mechanism of α1-blockers (e.g., prazosin), not α2 agonists. Clonidine does not block α1 receptors; it activates α2 receptors centrally. - **Stimulation of β2 receptors in the heart increases parasympathetic tone**: β2 receptors are not involved in clonidine's mechanism. Clonidine is an α2 agonist, not a β2 agonist. This option confuses receptor classes. - **Inhibition of β1 receptors in the myocardium reduces cardiac contractility**: β1 receptor inhibition is the mechanism of beta-blockers, not α2 agonists. While clonidine does reduce heart rate, this is secondary to reduced sympathetic outflow, not direct β1 inhibition. **High-Yield:** Clonidine's antihypertensive effect is central (brainstem α2 activation → ↓ sympathetic outflow), not peripheral. Abrupt withdrawal causes rebound hypertension due to sudden loss of this inhibitory effect. [cite: KD Tripathi 9e Ch 36 — Adrenergic Agonists and α2-Agonists]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.